These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 37171003)

  • 1. Italian Guidelines for the Management of Prolactinomas.
    Cozzi R; Simona Auriemma R; De Menis E; Esposito F; Ferrante E; Iatì G; Mazzatenta D; Poggi M; Rudà R; Tortora F; Cruciani F; Mitrova Z; Saulle R; Vecchi S; Basile M; Cappabianca P; Paoletta A; Papini E; Persichetti A; Samperi I; Scoppola A; Bozzao A; Caputo M; Doglietto F; Ferraù F; Lania AG; Laureti S; Lello S; Locatelli D; Maffei P; Minniti G; Peri A; Ruini C; Settanni F; Silvani A; Veronese N; Grimaldi F; Attanasio R
    Endocr Metab Immune Disord Drug Targets; 2023; 23(12):1459-1479. PubMed ID: 37171003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperprolactinemia: pathophysiology and management.
    Verhelst J; Abs R
    Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistant prolactinomas: a case series of 26 patients.
    Eshkoli T; Fraenkel M; Zaid D; Cohen D; Yoel U; Tsvetov G; Gorshtein A; Goldbart A; Greenman Y; Shimon I
    Endocrine; 2022 Aug; 77(2):349-356. PubMed ID: 35604631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
    Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
    Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Dopamine Agonist-Resistant Prolactinoma.
    Maiter D
    Neuroendocrinology; 2019; 109(1):42-50. PubMed ID: 30481756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on prolactinomas. Part 2: Treatment and management strategies.
    Wong A; Eloy JA; Couldwell WT; Liu JK
    J Clin Neurosci; 2015 Oct; 22(10):1568-74. PubMed ID: 26243714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of high-dose daily cabergoline in an adolescent patient with macroprolactinoma.
    Howell DL; Wasilewski K; Mazewski CM; Hudgins RJ; Meacham LR
    J Pediatr Hematol Oncol; 2005 Jun; 27(6):326-9. PubMed ID: 15956887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure.
    Akinduro OO; Lu VM; Izzo A; De Biase G; Vilanilam G; Van Gompel JJ; Bernet V; Donaldson A; Olomu O; Meyer FB; Quinones-Hinojosa A; Chaichana KL
    World Neurosurg; 2019 Sep; 129():e686-e694. PubMed ID: 31181361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal.
    Santharam S; Fountas A; Tampourlou M; Arlt W; Ayuk J; Gittoes N; Toogood A; Karavitaki N
    Clin Endocrinol (Oxf); 2018 Sep; 89(3):346-353. PubMed ID: 29894000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Prolactinoma.
    Inder WJ; Jang C
    Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolactin-secreting tumors, dopamine agonists and pregnancy: a longitudinal experience of a tertiary neuroendocrine center.
    Prencipe N; Bona C; Cuboni D; Berton AM; Bioletto F; Varaldo E; Aversa LS; Sibilla M; Gasco V; Ghigo E; Grottoli S
    Pituitary; 2024 Jun; 27(3):269-276. PubMed ID: 38499816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.
    Colao A; Di Sarno A; Landi ML; Scavuzzo F; Cappabianca P; Pivonello R; Volpe R; Di Salle F; Cirillo S; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 2000 Jun; 85(6):2247-52. PubMed ID: 10852458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
    Sabuncu T; Arikan E; Tasan E; Hatemi H
    Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine agonist for the rapid improvement of visual field defects in giant and macro-prolactinomas.
    Hacisahinogullari H; Canturk S; Dogansen S; Yarman S
    J Fr Ophtalmol; 2022 May; 45(5):511-518. PubMed ID: 35272874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotype and resistance patterns of 10 resistant prolactinomas.
    Araujo-Castro M; Abad López A; Aller Pardo J; Kanaan Kanaan L; Palacios García N
    Endocrinol Diabetes Nutr (Engl Ed); 2020 Mar; 67(3):194-204. PubMed ID: 31201099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remarkable effects of cabergoline in a patient with huge prolactinoma resistant to high-dose bromocriptine: case report.
    Kawabata Y; Ueno Y; Horikawa F; Miyake H; Miki N; Ono M
    Surg Neurol; 2008 Jan; 69(1):85-8; discussion 88. PubMed ID: 17967478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolactinomas Resistant to Dopamine Agonists: Pathophysiology and Treatment.
    Shimon I
    Arch Med Res; 2023 Dec; 54(8):102883. PubMed ID: 37689507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.